Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) EPS (Weighted Average and Diluted) (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed EPS (Weighted Average and Diluted) for 12 consecutive years, with $0.05 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 44.44% to $0.05 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.2, a 81.82% increase, with the full-year FY2025 number at $0.2, up 81.82% from a year prior.
  • EPS (Weighted Average and Diluted) was $0.05 for Q4 2025 at Niagen Bioscience, roughly flat from $0.05 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.09 in Q4 2024 to a low of -$0.13 in Q3 2021.
  • A 5-year average of -$0.02 and a median of -$0.01 in 2022 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 85.71% in 2021, then skyrocketed 20249.07% in 2025.
  • Niagen Bioscience's EPS (Weighted Average and Diluted) stood at -$0.07 in 2021, then skyrocketed by 57.14% to -$0.03 in 2022, then skyrocketed by 105.07% to $0.0 in 2023, then soared by 5819.87% to $0.09 in 2024, then plummeted by 44.44% to $0.05 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's EPS (Weighted Average and Diluted) are $0.05 (Q4 2025), $0.05 (Q3 2025), and $0.04 (Q2 2025).